Purple Biotech Ltd. is a clinical-stage company focused on advancing therapies to overcome tumor immune evasion and drug resistance to create treatments for cancer patients in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||₪1.46|
|52 Week High||₪1.21|
|52 Week Low||₪2.48|
|1 Month Change||-3.76%|
|3 Month Change||-6.53%|
|1 Year Change||-4.82%|
|3 Year Change||-71.24%|
|5 Year Change||-89.05%|
|Change since IPO||-99.21%|
Recent News & Updates
Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|PPBT||IL Pharmaceuticals||IL Market|
Return vs Industry: PPBT matched the IL Pharmaceuticals industry which returned -4.6% over the past year.
Return vs Market: PPBT underperformed the IL Market which returned 47.9% over the past year.
Stable Share Price: PPBT is not significantly more volatile than the rest of IL stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: PPBT's weekly volatility has decreased from 11% to 6% over the past year.
About the Company
Purple Biotech Ltd. is a clinical-stage company focused on advancing therapies to overcome tumor immune evasion and drug resistance to create treatments for cancer patients in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company’s marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension.
Purple Biotech Fundamentals Summary
|PPBT fundamental statistics|
Is PPBT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PPBT income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.059|
|Net Profit Margin||0.00%|
How did PPBT perform over the long term?See historical performance and comparison
Is Purple Biotech undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PPBT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PPBT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PPBT is unprofitable, so we can't compare its PE Ratio to the Asian Pharmaceuticals industry average.
PE vs Market: PPBT is unprofitable, so we can't compare its PE Ratio to the IL market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PPBT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PPBT is good value based on its PB Ratio (1.1x) compared to the IL Pharmaceuticals industry average (1.8x).
How is Purple Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Purple Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Purple Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PPBT is currently unprofitable.
Growing Profit Margin: PPBT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PPBT is unprofitable, and losses have increased over the past 5 years at a rate of 17.9% per year.
Accelerating Growth: Unable to compare PPBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PPBT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.9%).
Return on Equity
High ROE: PPBT has a negative Return on Equity (-14.52%), as it is currently unprofitable.
How is Purple Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: PPBT's short term assets ($50.0M) exceed its short term liabilities ($3.5M).
Long Term Liabilities: PPBT's short term assets ($50.0M) exceed its long term liabilities ($870.0K).
Debt to Equity History and Analysis
Debt Level: PPBT is debt free.
Reducing Debt: PPBT had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PPBT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PPBT has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 17.1% each year.
What is Purple Biotech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PPBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PPBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PPBT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PPBT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PPBT's dividend in 3 years as they are not forecast to pay a notable one for the IL market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Isaac Israel (43 yo)
Mr. Isaac Israel has been the Chief Executive Officer of Purple Biotech Ltd. (formerly known as Kitov Pharma Ltd). (formerly, Kitov Pharmaceuticals Holdings LTD.) since October 2012.Prior to joining Kitov...
CEO Compensation Analysis
Compensation vs Market: Isaac's total compensation ($USD1.13M) is above average for companies of similar size in the IL market ($USD414.84K).
Compensation vs Earnings: Isaac's compensation has increased whilst the company is unprofitable.
Experienced Management: PPBT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: PPBT's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Purple Biotech Ltd.'s employee growth, exchange listings and data sources
- Name: Purple Biotech Ltd.
- Ticker: PPBT
- Exchange: TASE
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₪257.367m
- Shares outstanding: 176.16m
- Website: https://purple-biotech.com
Number of Employees
- Purple Biotech Ltd.
- 4 Oppenheimer Street
- Science Park
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/24 22:28|
|End of Day Share Price||2021/10/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.